Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultralife (ULBI) Payables (2016 - 2025)

Ultralife (ULBI) has disclosed Payables for 16 consecutive years, with $17.4 million as the latest value for Q4 2025.

  • For Q4 2025, Payables rose 23.04% year-over-year to $17.4 million; the TTM value through Dec 2025 reached $17.4 million, up 23.04%, while the annual FY2025 figure was $17.4 million, 23.04% up from the prior year.
  • Payables hit $17.4 million in Q4 2025 for Ultralife, up from $14.2 million in the prior quarter.
  • Across five years, Payables topped out at $19.0 million in Q1 2023 and bottomed at $9.2 million in Q3 2021.
  • Average Payables over 5 years is $13.4 million, with a median of $13.4 million recorded in 2022.
  • Year-over-year, Payables soared 71.92% in 2022 and then crashed 47.73% in 2024.
  • Ultralife's Payables stood at $9.8 million in 2021, then surged by 61.12% to $15.8 million in 2022, then decreased by 28.38% to $11.3 million in 2023, then rose by 24.91% to $14.2 million in 2024, then increased by 23.04% to $17.4 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $17.4 million, $14.2 million, and $15.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.